微信直播

WCLC 2017专访 | Dr. Giannis Mountzios:免疫疗法,一个全新而重要的领域

Published at: 2015年第1卷第S1期

晨 凌
关键词:

编者按2017年10月15-18日,第十八届世界肺癌大会(WCLC 2017)于在日本横滨成功举办。作为全球最大的致力于肺癌和其他胸部恶性肿瘤的多学科肿瘤学会议,席间除了可以获取到这方面的最前沿治疗进展资讯,还可以与来自世界各地的会议代表和世界知名专家进行互动交流。十分荣幸地,AME出版社在会后采访了来自希腊雅典大学的Dr. Giannis Mountzios

人物聚焦:Giannis Mountzios

Dr Giannis Mountzios (MD, MSc, PhD) was born in Larissa, Greece, in 1974. He obtained his Medical Degree (MD) from the Aristotle University of Thessaloniki in 1998 with a scholarship from the Greek Ministry of Education and graduated from the Hellenic Military Medical Academy the same year. He completed his residency in Internal Medicine at the 251 Air force General Hospital of Athens and in Medical Oncology at the University of Athens School of Medicine, “Alexandra” University Hospital.

He then obtained a Master (MSc) in Translational and Clinical Research in Oncology from the Institut Gustave-Roussy and the University Paris XI (Paris-Sud), France, in 2007 and became board-specified in Medical Oncology in 2009.

In 2010 he obtained his PhD in Medical Oncology from the University of Athens School of Medicine.

Dr Mountzios is currently working as a consultant Medical Oncologist at the Department of Medical Oncology in the Air force General Hospital in Athens.

Dr Mountzios has received fellowships from the American Society of Clinical Oncology (ASCO), the European Society for Medical Oncology (ESMO) and the Hellenic Society for Medical Oncology (HESMO).

He is a member of the Board of Directors of HESMO and previous chair of the HESMO young medical oncologists committee. From 2012 to 2014, Dr Mountzios was a member of the ESMO Young Oncologists Committee.

图. Dr. Giannis Mountzios与AME编辑合影

作为一名相对年轻的肺癌研究专家,Dr. Mountzios与我们分享了他对于免疫疗法的一些看法。他认为,免疫疗法在治疗癌症方面是一个全新而重要的领域。肿瘤家们第一次见证了使用免疫疗法,使得具有高肿瘤负荷且发生癌症转移的患者的生存期得以延长,而且也避免了经典化疗所带来的相关毒性。然而不幸的是,并不是所有患者都能从免疫治疗中受益,因为并不是所有的肺肿瘤都对免疫治疗有反应。这将取决于肿瘤对我们的身体免疫系统的攻击有多“敏感”,将来有可能对被认为“不敏感”的肿瘤通过施用“免疫刺激”试剂而使之变得适合于免疫疗法。

对于未来的研究方向,Dr. Mountzios认为主要集中在两个方面。首先,我们需要找出理想的生物标记物,这可以安全地预测通过单独的免疫疗法能实现长期生存的患者亚组。其次,我们需要把研究重点集中在那些对于单纯免疫治疗无法治愈的患者身上:我们应该首先确定对于这些患者而言最佳的治疗组合方式,是免疫治疗与化学疗法还是放疗和其他免疫治疗相结合。这能让我们找出这些患者能从哪些组合中受益,并同时也可以尽量避免不必要的治疗毒性。

作为一名胸科肿瘤医师,最大的和最令人着迷的挑战是,你每天都在科学和知识的边缘学习。我们今天突破新疗法的速度是前所未有的,这是一个非常有竞争力的领域。我们的患者都应得最好的治疗,这一点毋庸置疑。这种为知识而努力的工作,使我在肿瘤学方面有所收获,也更让我坚定地选择肺癌作为我的研究领域。

  1. The advent of immunotherapy has changed the treatment paradigm of lung cancer. However, it IS still hard for medical staff to choose the suitable patients candidate to receive immunotherapy. How do you think about it?

  2. Some people may say, there will be a day when immunotherapy finally replace chemotherapy as the front-line therapy for advanced lung cancer. What is your opinion on it? 

  3. What do you think is the future research direction in the field of immunotherapy?

  4. Along the way to be an excellent researcher, would you like to share with us any stories behind? What encourage you to choose the career/field?


采写编辑:凌晨 AME Publishing Company

特别鸣谢阎石医生对采访问题的指导

comments powered by Disqus

附件